Home : Drug Policy : Marijuana Law Reform

In the Matter of Lyle Craker - Congressional Sign-On Letter (09/18/2007)
A letter signed by 45 members of Congress urging DEA Administrator Karen Tandy to follow an administrative law judge's recommendation and grant Professor Lyle Craker a license to cultivate marijuana for use in FDA-approved studies aimed at developing marijuana as a prescription medicine.

Testimony of Valerie Corral at the House Judiciary Committee's Oversight Hearing on DEA's Regulation of Medicine (07/12/2007)
Written testimony of Valerie Corral, founder of the Wo/Men's Alliance for Medical Marijuana (WAMM), a medical marijuana hospice, prepared for presentation before the U.S. House of Representatives Committee on the Judiciary, Subcommittee on Crime, Terrorism, and Homeland Security during oversight hearings on the Drug Enforcement Administration's regulation of medicine. Corral addresses the federal government's policies of obstructing state medical marijuana legislation as well as legitimate scientific research. [Note that spoken testimony may not directly reflect this document]

ACLU Letter to the House of Representatives Urging Members to Vote For The Hinchey/Rohrabacher/ Paul/Farr Amendment To The Science-State-Justice-Commerce Appropriations Bill (06/26/2006)

Santa Cruz, California's Proposed Ordinance Establishing an "Office of Compassionate Use" to Provide Medical Marijuana to Qualified Patients (11/07/2005)

ACLU Letter to the House Urging Support of the Farr-Rohrabacher Medical Marijuana Amendment and the Flake Amendment on Travel to Cuba to the FY 2005 Commerce, Justice, State, and Judiciary Appropriations Bill (07/06/2004)

Letter to the House Government Reform Committee on the Medical Marijuana Provisions of H.R. 2086, the Office of National Drug Control Policy Reauthorization Act of 2003 (05/21/2003)

Sign-on Letter to the House Urging Opposition to H.R. 2155, the Sober Borders Act (10/15/2002)

Letter to the Senate in Opposition to Anti-Democracy Riders to the DC Appropriations Bill (10/25/2001)

Letter to the Senate Regarding the Hatch Drug Amendment to S. 625, the "Bankruptcy Reform Act of 1999" (11/08/1999)

Testimony of Executive Director Ira Glasser on National Drug Policy (06/16/1999)